摘要
目的探讨恩格列净联合阿卡波糖在冠状动脉粥样硬化性心脏病(coronary atherosclerotic heart disease,CHD)合并2型糖尿病(type 2 diabetes mellitus,T2DM)患者治疗中的效果及安全性。方法于2021年1月—2024年12月,方便选取漳州第三医院治疗的120例CHD合并T2DM患者,按照不同治疗药物分为对照组(阿卡波糖)和观察组(恩格列净联合阿卡波糖),两组各60例。分析两组糖脂水平与不良反应总发生率改善程度。结果治疗后的糖化血红蛋白、空腹和餐后2 h血糖、高密度及低密度脂蛋白胆固醇、总胆固醇、甘油三酯数据显示,观察组相较于对照组改善更明显,差异均有统计学意义(P均<0.05)。对照组不良反应发生率为6.67%(4/60),低于观察组的10.00%(6/60),但差异无统计学意义(χ2=0.436,P>0.05)。结论恩格列净联合阿卡波糖治疗CHD合并T2DM患者可有效改善患者的糖脂代谢水平,且安全性良好。
Objective To explore the efficacy and safety of empagliflozin combined with acarbose in the treatment of patients with coronary atherosclerotic heart disease(CHD)complicated with type 2 diabetes mellitus(T2DM).Methods From January 2021 to December 2024,120 patients with CHD and T2DM treated in Zhangzhou Third Hospital were convenient selected and divided into control group(acarbose)and observation group(empagliflozin combined with acarbose)according to different treatment drugs,each group had 60 cases.The improvement of glucose and lipid levels and the total incidence of adverse reactions in the two groups were analyzed.Results The data of glycated hemoglobin A1c,fasting and 2-hour postprandial plasma glucose,high density and low density lipoprotein cholesterol,total cholesterol and triglyceride after treatment showed that the improvement of the observation group was more obvious than that of the control group,and the differences were statistically significant(all P<0.05).The total incidence of adverse reactions in the control group was 6.67%(4/60),which was lower than 10.00%(6/60)in the observation group,but the difference was not statistically significant(χ2=0.436,P>0.05).Conclusion Empagliflozin combined with acarbose can effectively improve the levels of blood glucose and lipids in patients with CHD and T2DM,and has good safety.
作者
戴泽龙
邓节喜
DAI Zelong;DENG Jiexi(Department of Cardiology and Vascular Intervention,Zhangzhou Third Hospital,Zhangzhou 363000,Fujian,China)
出处
《糖尿病新世界》
2026年第1期99-102,共4页
Diabetes New World
关键词
恩格列净
阿卡波糖
冠状动脉粥样硬化性心脏病
2型糖尿病
糖脂水平
不良反应
Empagliflozin
Acarbose
Coronary atherosclerotic heart disease
Type 2 diabetes mellitus
Blood glucose and lipid levels
Adverse reactions
